The major findings were proved to be robust across various scenarios when tested in sensitivity analysis.
Conclusions:
The review confirmed the cost-effectiveness not only of HIV universal antenatal screening but also of rescreening in late gestation in both developed and developing countries. Universal screening is cost-effective even in case of extremely low HIV prevalence. Therefore, to maximize screening, coverage theme. For these reasons, our review investigates the cost-effectiveness of HIV screening in MCTC prevention, in order to provide a clear summary of the different views regarding the evidence that support this practice, both in developed and developing countries.
| METHODS
For the present systematic review, we followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statements. 33 To summarize the existing evidence regarding the antenatal HIV screening cost-effectiveness, we used multiple research strategies. Firstly, we decided to consider the papers reporting data about cost-effectiveness of the different HIV-screening strategies used to avoid MTCT.
Given these premises, we conducted our research on the following 3 databases: Cost-Effectiveness Analysis Registry, PubMed, and Scopus. Two researchers (EC and MM) independently performed a systematic research using the following strings: "HIV screening" AND cost effectiveness; "HIV test" AND cost effectiveness; "HIV screening" AND cost effectiveness AND pregnancy; "HIV screening" AND cost effectiveness AND pregnant;
Antenatal "HIV test" AND cost effectiveness.To select the eligible studies, we used the inclusion criteria reported below:
• Cost-effectiveness studies regarding the screening of HIV vertical transmission;
• Papers written in English, French, Italian or Spanish language; and
• Publication date from 2000 onwards
We decided to set a time limit to our research (from 2000 onwards) because it coincides with the wide introduction of effective AntiRetroViral (ART) regimens. 34 We did not perform restrictions according to the country in study. Moreover, we considered both simulation models and clinical trials.
Articles were considered ineligible if:
• They exclusively focused on cost-effectiveness analysis of therapies
• They only considered costs analysis After this criteria selection, the investigators independently carried on a first literature screening, sorting the sources by title and abstract. During this first selection procedure, all the irrelevant or redundant results were excluded. Following this, we collected eligible studies for full text review. Moreover, the authors completed their research by assessing the reference list of the retrieved articles. Finally, the researchers independently evaluated each of the selected articles by following the characteristics described in the abovementioned inclusion and exclusion criteria.
| Data extraction
To summarize the results, the researchers independently extracted the data of interest, solving any disagreement by consensus. For each article, we collected data about the country of study, the outcomes, the target population, settings, time horizons, proposed perspectives, intervention strategies, different types of HIV test, HIV's prevalence or incidence during pregnancy, and finally data referring to costs and results. Figure 1) . Tables 1 and 2 summarize the main characteristics of the considered studies. More precisely, Table 1 reports the general characteristics of the retrieved studies (including settings, types of intervention, HIV prevalence, and outcomes), while Table 2 summarizes the economic characteristics of the works (including actual expenses, cost perspectives, currency, reference year, and results).
To limit the risk of introducing biases into our systematic review, the quality of the studies was assessed using the Drummond 10-item scale. 35 This scale is composed of 10 main questions, which are further divided into subitems. For example, the first item investigates the main aim of the analysis, inquiring if the objective of the study is built in an answerable form. Most of the remaining questions consider the evaluation of the costs and the consequences of the interventions. 36 All the studies included resulted to be valid, thus presenting a score of 7 or higher (see Table 1 ).
The chosen studies were conducted in all 5 different continents, including countries with different population's average income and HIV burden. All studies were published between 2000 8,37,38 and 2015. 28 Almost all studies
The figure reported the flow chart of our systematic review regarding the HIV screening costeffectiveness in pregnancy (n = 19) are simulation models, [4] [5] [6] [7] [8] [11] [12] [13] 17, 19, 27, [29] [30] [31] [32] [37] [38] [39] [40] while the last 2 works, both conducted in India, are clinical trials. 14, 28 Regarding the economic analysis, 5 papers adopted a societal perspective, 8 Table 1 ).
| Universal antenatal screening
Seven works investigated the cost-effectiveness of universal antenatal screening, [4] [5] [6] [7] 11, 27, 37 comparing this strategy to other approaches such as voluntary screening, 7, 11, 37 no screening, 4, 5, 37 or targeted screening. 27 See Table 1 for the general characteristics and Table 2 for the economic items. The universal approach provides to pregnant women an HIV antenatal test by default, yet maintaining the possibility of an informed refusal by the pregnant woman. All the retrieved works underlined the economic and health benefits of a similar programme. In particular, 2 works compared 3 different approaches, namely, a universal screening, a voluntary one, or an optional one. 11, 37 Both studies identify the universal strategy as the best approach in terms of cost-effectiveness. More precisely, the study conducted in the US setting has shown how the universal approach appeared to be cost saving when compared not only to no screening but also to the voluntary strategy. 37 These findings turned out to be robust across sensitivity analysis, and the universal strategy remained cost-effective until a very low HIV prevalence (0.0075%). Whenever HIV prevalence among pregnant women was ≥0.21%, the universal approach appeared to be cost saving. 37 Similarly, in the second study focused on Colombia social situation, the universal screening presented a better efficacy and lower
costs in all the scenarios tested in sensitivity analysis.
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Four works focused specifically on the cost-effectiveness of universal screening in countries with a very low HIV burden, 4-7 thus considering an HIV prevalence ranged between 0.02% and 0.09%. [4] [5] [6] [7] These studies compared the universal screening to the current screening activities 6, 7 or to the absence of screening. 4, 5 Particularly, Bramley et al evaluated the cost-effectiveness of the implementation of a universal screening programme in New Zealand, compared to routine care. Even in a country with such a low prevalence rate (0.03%), the universal approach appeared to be cost-effective. 7 Graves et al confirmed these findings by considering a hypothetical cohort of Australian pregnant women. Indeed, this kind of intervention appeared to be cost-effective whenever the undiagnosed HIV prevalence exceeded 0.0044%, and the health benefits raised after the increasing of this rate. 6 Furthermore, a more recent study assessed the cost-effectiveness of universal screening in the Public Antenatal Clinics of Hong Kong, another country experiencing low HIV prevalence. This programme was found to be well within the national cost-effectiveness thresholds. 5 Finally, Rozenbaun et al evaluated the cost-effectiveness of a universal screening in Amsterdam compared to no screening. This strategy presented an opt-out approach with an acceptance rate exceeding 99%. The screening presented a net cost saving of 97 707€ versus no screening. 4 In summary, all papers confirmed the cost-effectiveness of universal antenatal screening even in extremely low-prevalence countries.
Moreover, similar interventions that were favourably compared to other preventive interventions are already taking place in the considered countries. All the results appeared to be robust in sensitivity analysis. However, the most influencing parameters identified through the analysis were the undiagnosed HIV prevalence in pregnant women, 4, 5, 7 the testing uptake, 5, 6 the life expectancy of HIV infected subjects, 4 and the losses to follow-up. 5 Finally, one study was conducted in India, a country with a higher HIV prevalence than the others abovementioned (prevalence: 0.75% nationwide, 1.3% in high-risk regions). 27 The authors considered 2 possible initiatives: nationwide universal screening and targeted screening focused to high-prevalence regions. The results
showed that the targeted strategy would cost significantly less than the nationwide intervention, preventing nearly 50% of total newborn infections. After the sensitivity analysis was performed, the most influential parameters found were the following: antenatal coverage rate, HIV-test costs, and lifetime treatment costs. 27 As expected, HIV antenatal screening were found to be clearly cost-effective in countries with an important HIV burden.
| Integrating HIV antenatal screening with other health care programmes
Two studies investigated the cost-effectiveness following the integration of HIV antenatal screening with other health care programmes. 13, 14 These works concluded that the combination of multiple antenatal screenings was economically worthwhile. In particular, a Chinese study investigated the health and economic outcomes deriving from the association of HIV and syphilis tests compared to no screening or to HIV and syphilis screenings performed separately.
The integrated strategy appeared to be the most cost-effective option. 13 The second study, conducted in the Maharashtra region (India), evaluated the cost-effectiveness of the integration of antenatal HIV screening within maternal and child health programmes, to increase the testing uptake. The author compared this innovative approach to the situation prior the implementation of this service. The integration programme consented to significantly increase the screening coverage and the detection of HIV infected women, reaching a 29% growth of case identifications. Moreover, the considered integration determined other benefits including high linkage to care for the mothers (93%) and a prophylaxis coverage of 92%. 
| Test in late pregnancy
Since women could acquire HIV infection during pregnancy, some studies investigated the importance of HIV testing during late pregnancy. In particular, 8 studies assessed the cost-effectiveness of HIV screening during this gestational period (see Table 1 for general characteristics and Table 2 for economic items). 17, [28] [29] [30] [31] [32] 38, 40 All studies were published between 2000 38 and 2015. 28 Most of the studies compared the addition of a second test in late pregnancy or during labour to antenatal screening only. [28] [29] [30] [31] [32] 38 In particular, 3 studies investigated the implementation of a rescreening programme in countries with low HIV prevalence rates. 31, 32, 38 These works highlighted the potential role of rescreening even in countries with a limited HIV burden. In particular, Postma et al estimated the role of HIV rescreening in London within a programme of universal testing in early pregnancy. In this case, both the universal and the selective approaches (limited to high-risk groups) were evaluated, and the universal rescreening appeared to be cost-effective. Also, a targeted rescreening appeared as a cost-effective choice compared to the fixed threshold. Furthermore, after performing a sensitivity analysis, the authors observed that the high-risk targeted screening was cost-effective within a wide range of test costs. In particular, this screening strategy was cost-effective even assuming a particularly high range of test costs (10-40£). In this specific range of costs, a targeted rescreening was more cost-effective than the universal approach. 38 A similar cost-effectiveness analysis of Sansom et al focused on the US setting. The analysis evaluated the rescreening strategy nationwide and limited to high-risk communities. The programme offered a second test during the 32nd week of pregnancy to women negative at first screening. The targeted rescreening appeared to be cost saving in all the scenarios tested through a sensitivity analysis. Moreover, the universal retesting strategy was effectively cost saving when HIV incidence exceeded 32 1.2 per 1000. Finally, the third study analysed the cost-effectiveness of a second HIV screening during late gestation in Thailand. The second test was found to be cost-effective, with a cost of 1266 US$ per averted case. 31 Moreover, the cost-effectiveness of HIV rescreening during late pregnancy was widely assessed in resourcelimited countries with high HIV burden. [28] [29] [30] Soorapanth et al in 2006 assessed the cost-effectiveness of a similar programme in South Africa. The programme consisted of retesting pregnant women using an HIV rapid test around the 28th to 34th week of pregnancy. The rescreening strategy turned out to be cost saving when the prophylaxis was available (saving 557 201$), and cost-effective even when the therapy resources were lacking (12.34$ per QALY saved). These findings were confirmed across a wide range of assumptions. Moreover, the reduction of the interval between the first and second test translated into a decrease in infections averted and consequently in lower savings. 30 The cost-effectiveness of HIV rescreening was assessed, also, in Uganda, where Kim et al investigated the implementation of the same programme, using the WHO cost-effectiveness threshold of ≤3xpro-capitaGDP. Moreover, the authors estimated the potential addition of HIV-RNA test, to identify acute infections. This model individuated the rescreening at delivery as the most cost-effective option. This finding appeared widely confirmed by a sensitivity analysis. However, when the HIV incidence exceeded 8%, a multicomponent strategy including an early pregnancy test, a second rapid test and an HIV-RNA test at delivery became the most worthwhile option. 29 Moreover, a recent cost-effectiveness analysis evaluated HIV rescreening in Indian antenatal clinics, by offering a second HIV rapid test to uninfected pregnant women. Performing only an early screening appeared to be less cost-effective than the rescreening programme. 28 Another work considered the implementation of a rescreening programme targeted specifically at a high-risk group as women without adequate prenatal care in the United States. These women presented higher HIV prevalence than general population. The study considered 2 opposite strategies, respectively, no testing or an HIV rapid test followed by an adequate prophylaxis in case of positive results. The screening intervention was found to be cost saving (over 3 million $/year). When the performance of a rapid test was not feasible (no test availability or low acceptance rate), the empiric prophylaxis appeared to be cost saving compared to no intervention. The key influencing items pointed out by the sensitivity analysis were vertical transmission probability, rescreening acceptance rate, and the amount of women receiving adequate and effective prophylaxis. In particular, the intervention was cost-effective also considering a lower prevalence rate, such as the general population prevalence rate. 
| Multiple testing analysis
Finally, 4 works compared the use of multiple testing strategies, including antenatal screening, late pregnancy test, and newborns testing in different combinations. 8, 12, 19, 39 All the studies were published between 2000 8 and 2008. 19 The main characteristics of these works are summarized in Tables 1 and 2. More precisely, Udeh et al assessed the cost-effectiveness of different perinatal screening strategies in US Virgin
Islands, a high-prevalence HIV setting. The 9 strategies considered were matched to different combinations of the 3 following interventions: early antenatal screening, screening during labour, and newborns testing. Each intervention was compared to the existing practice (actual HIV test coverage in pregnancy <30%). The model outlined the benefits and savings for all the approaches. However, the best combination among all strategies was made of early pregnancy screening with newborns testing. Ultimately, the most influential parameters outlined by the sensitivity analysis were HIV-infected subjects life expectancy and vertical transmission probability. 19 Another analysis evaluated the cost-effectiveness of 6 different MTCT prevention strategies in Mexico including increasing HIV test coverage, a targeted HIV screening to high-risk women, and the integration of antenatal screening with rescreening for not previously tested women. All these strategies were compared to status quo. The strategy including antenatal screening plus screening during labour for nonpreviously tested women was the most cost-effective intervention. This approach appeared to be more useful than all the other alternatives. Moreover, this study assessed the possible impact of HIV screening on behavioural changes. The cost-effectiveness ratio of all the considered interventions also improved when considering the impact on women behaviours. 39 One US study focused on a specific high-risk group like incarcerated pregnant women. The study analysed 3 different strategies alone or in combination: Voluntary Prenatal Screening (VPS), Routine Prenatal Screening (RPS), and Mandatory Newborn Screening (MNS). In RPS, women can refuse testing, but they are not explicitly asked to accept it. The most effective strategy was found to be the association of RPS with MNS. This combination strategy was proved to be better than the other options. However, when MNS was not feasible, the best alternative was RPS, instead of the VPS option, which proved out to be cost saving compared to no screening. Even if increasing the VPS acceptance rate to the community rate (84%) had slightly affected the results, RPS remained the most favourable strategy. 12 Finally, Zaric et al evaluated the cost effectiveness of 2 different hypothetical screening strategies in the United
States, namely, an enhanced prenatal screening and the addition of a mandatory routine newborn screening, both compared to current practice. The enhanced strategy consented to increase the coverage of screening from the actual value of 65% to nearly 95%. The newborn screening consisted of a first test performed immediately after birth (newborns with a positive test received adequate prophylaxis) and a confirmation test performed after 6 weeks.
Enhanced screening was cost-effective, with an incremental cost-effectiveness rate of 8900 US$ per LYG. The newborn screening was cost-effective (7000 US$ per LYG). If the enhanced voluntary screening is already taking place, the additional newborn screening experienced an increase in the cost-effectiveness ratio reaching the value of 10 600$ per LYG. The cost-effectiveness of newborns screening progressively decreased as the antenatal test coverage increased. However, after a sensitivity analysis, all the options considered presented a cost-effectiveness rate lower than 36 000 US$ per LYG. 8 Summarising, all previous studies outlined the cost-effectiveness of different screening approaches combined.
However, the optimal strategy depends, mainly, on the characteristics of the population in study.
| DISCUSSION
Vertical transmission during pregnancy, delivery, or lactation represents the most important route of HIV infection among children. 1 The preventive interventions available were found to be extremely effective. 15 To choose the optimal antenatal HIV screening strategy, policy makers need detailed cost-effectiveness analysis, assessing all potential scenarios. Thus, our systematic review aims to summarize the existing evidence regarding the cost-effectiveness of MTCT screenings. The cost-effectiveness of universal antenatal testing during early pregnancy is widely assessed in both developed 4, 37 and limited resources countries. 19, 27 The cost-effectiveness of the first trimester screening improved after the increasing of HIV prevalence rate among pregnant women. However, this intervention resulted economically favourable even in countries presenting extremely low HIV prevalence rates. 4, 6, 7 The main benefit of the screening test was the high number of HIV newborn averted cases, but some studies considered in addition the gain in life expectancy for infected mothers and babies, which also appears to be related to early detection. 6, 7 About this point, studies considering HIV screening on adult population outlined the economical and health benefits deriving from an early diagnosis in terms of both quantity and quality of life. 25, 26 Some other studies estimated the impact of different approaches, identifying the universal approach as the most cost-effective strategy when compared not only to no screening but also to voluntary approach. 11, 12, 37 Indeed, universal screening, consisting of testing by default all pregnant women, maximizes the screening coverage. 4, 11, 37 International researches pointed out that women who were unaware of their HIV serology were more likely to accept a test when this was presented as a routine analysis, rather than a test proposed because of their high-risk behaviours. 41, 42 This observation is extremely important considering that one of the most influencing parameters for the outcomes is women's acceptance rate. Given the proven high use of Internet in seeking health information about pregnancy, this valuable instrument could effectively be used in to increase women's acceptance rate. 43 In addition, the use of integrated strategies, which combine HIV testing with other prenatal screenings or with mother and child standard care, consented to increase test uptake. 13, 14 However, screening tests targeted at high-risk groups appeared to be a cost-effective tool in the prevention of vertical transmission of HIV. 27, 32, 38 This strategy was proved to be particularly valuable when universal screening was not practically feasible, for example, in settings without the economic resources to provide the universal programme.
Another problem, affecting primarily developing countries, is represented by the reduced access of pregnant women to antenatal care and consequently to testing. 27 Therefore, improving antenatal services attendance should be a priority. Since women with a poorer access to antenatal care generally presented a higher HIV burden, 40 benefits could increase exponentially by increasing this access rate. Moreover, comparing voluntary to universal approach, the authors assumed a conservatory high value of voluntary acceptance rate; therefore, the outlined savings of universal testing could even be underestimated. 37 Furthermore, even if mandatory newborn testing appeared as an economically worthwhile option, 8, 12 a similar policy is not always legally feasible. However, the newborn testing appeared to be cost-effective not only for high-risk groups like incarcerated pregnant women 12 but also when a highly effective prenatal screening is performed nationwide. 8 Most studies did not take into account in this model the impact of screening intervention on mothers' highrisk behaviours, possibly underestimating the screening's cost-effectiveness. Indeed, the only study evaluating this parameter assessed a further improvement in the incremental cost-effectiveness ratio. 39 The behavioural impact could also prevent a number of horizontal transmission cases, thus making the considered screening even more interesting. Indeed, Marks et al estimated an annual transmission rate of 6.9% for people unaware of their infection versus 2% for individuals who were aware of their condition. 44 Some studies also outlined the important role played by counselling in encouraging the partners to perform the test. 28, 38 In fact, this kind of intervention appeared to be cost saving.
The robustness of the previously reported findings was confirmed in nearly all of the scenarios that were tested through a sensitivity analysis. In particular, the screening remained cost-effective even when the HIV prevalence ratio, the costs of the test, and the screening acceptance rate varied within a wide range of assumptions. The sensitivity analysis allowed to minimize the uncertainty due to the paucity of exact data regarding some key factors (as HIV prevalence ratio among pregnant women, life expectancy in infected children, or lifetime treatment costs). The availability of more accurate statistics would make the results even more solid. However, since treatment regimens and costs are evolving rapidly, it is getting more difficult to predict with certainty the survival benefits and lifetime costs.
Many studies have considered only the costs incurred by health care sector 4, 7, 39 ; however, other costs could also be significant, as time costs. Furthermore, it is important to assess the so-called negative benefits, including mothers' psychological burden. These items should be considered, inasmuch they could significantly affect the value of the resulting cost-effectiveness ratio.
Most of the retrieved studies assessed the discounted future costs and benefits, using a discount rate ranging from 3% 6, 8, 19, 37 to 5%. 27 The optimal discounting rate and whether to use or not the same rate for both benefits and costs is still debated. 45 To assess this uncertainty, different ranges of discounting rates were tested in sensitivity analysis, not affecting anyway primary findings. The cost-effectiveness thresholds differed amongst the retrieved studies, but the most commonly used were the WHO threshold of ≤3xprocapitaGDP 29 or the conventional limit of 50 000US$/QALY 40 or per life year saved. 37 Anyhow, all studies outlined that the incremental cost-effective ratios of HIV antenatal or late pregnancy screenings are favourably compared to preventive interventions, which are already taking place in the country in study. However, it is important to consider the specific policy context of the country in analysis. Indeed, cost-effectiveness is often a subjective term, and it is essential to assess the economic planning of the considered settings. Each strategy, even the cost-saving ones, required an initial investment that should be carefully planned. However, the significant health benefits retrieved in our review suggest the importance of an economic effort in this context. Furthermore, the results of the retrieved studies outline the potential savings that could be achieved through the years by following the introduction of similar screenings.
Especially in countries with high HIV incidence, infections during pregnancy (between early testing and delivery)
represent an important risk for vertical transmission. 29, 30 In this sense, the implementation of a rescreening strategy in late pregnancy or during labour could be an interesting solution. The cost-effectiveness of similar interventions is widely assessed in high-risk countries, such as South Africa or Uganda, 29, 30 but also in countries with lower incidence rates and limited resources, such as Thailand. 31 The South African study assessed, also, the best interval between first and second testing, evaluating the worsening in cost-effectiveness when shortening this interval. 30 Therefore, the best timing for testing must be carefully considered. The cost-effectiveness of HIV rescreening was favourably assessed, also, in developed countries within an effective universal screening programme. 32, 38 Finally, screening during late pregnancy can be effective in increasing the coverage rate, by targeting similar interventions at previously unscreened women. 39, 40 Women without an adequate prenatal care could benefit of similar tests, considering also the higher HIV prevalence amongst this group. 40 The type of test used in the various screening strategies differed. Some interventions used standard HIV antibody test combined with pretest and posttest counselling, 6, 7 while others used rapid HIV testing. 30 In particular, for the repeated screening, the importance of rapid tests has been proven, presenting a better cost-effectiveness ratio than rescreening using standard ELISA test. 17 More generally, the main limitations were to assume an equivalent prevalence rate among women who accepted and those who refused HIV testing, 7 the lack of consideration of possible antiretroviral adverse effects, 4 not assessing indirect medical costs, 4, 7, 40 and assuming that HIV screening results did not significantly affect women's reproductive choices. 4 Furthermore, some studies, focusing on more specific local situations, 14 could present limits of generalizability. Moreover, models are always a simplification of the complexity of actual events. Finally, the exclusive inclusion in our review of papers written in English, French, Italian, or Spanish may have led to miss some other works potentially important.
All studies outlined the effectiveness and economic attractiveness not only of universal antenatal screening but also of rescreening in late pregnancy or during labour. The conservative assumptions made indicated that the favourable cost-effectiveness ratios of these interventions could even be underestimated, hence outlining the importance of these programmes' implementation worldwide. To maximize benefits, it is important to reach the maximum coverage possible, minimize the losses to follow-up, and containing as much as possible all the derived costs. To optimize the testing uptake, the universal approach, the use of integrated programmes, and the recovery of previous untested women at delivery appeared all successful and economical worthwhile options. Moreover, it would be interesting to investigate the possible differences in testing uptake related to the type of test (blood sample or saliva).
Our study did not focus specifically on the alternative prophylaxis regimens available. However, one of the retrieved studies identified as the best option, showed the most effective regimen in decreasing transmission, independently from costs, highlighting that even a modestly effective prophylaxis regimen was cost-effective. 40 Even when an adequate antiretroviral prophylaxis is not available, the maternal HIV screening appeared to be cost-effective. 30 In high-risk women not previously tested, when HIV rapid test during labour is not feasible, the empirical treatment appeared to be cost-effective. 40 The characteristics and methodologies of the retrieved studies were heterogeneous, for example, some analysis adopted a societal perspective 19, 37, 40 while others preferred a health care system perspective. 4, 5, 27, 29 However, despite these differences, all studies agreed upon the main findings. In conclusion, our review confirmed the cost-effectiveness, not only of HIV universal antenatal screening but also of rescreening in late gestation in both developed and developing countries. In fact, HIV screening resulted cost-effective even in case of extremely low HIV prevalence ratios. Further studies assessing the optimal HIV-test choice (standard ELISA test versus HIV rapid tests) and the best testing sequence for confirmation (including repeated antibody test plus Western Blot confirmation or WB-alone) could be useful.
| CONCLUSIONS
In summary, the cost-effectiveness of universal HIV screening in pregnancy is widely proved. Moreover, a targeted screening towards high-risk women also appears as a cost-effective choice, presenting even lower initial costs than the universal strategy. Therefore, targeted screening could be a precious alternative in settings or countries where universal screening is not a feasible solution. Moreover, for some countries, the costs of the universal approach appear to be excessive, when considered in the context of economic planning. In these settings, the implementation of a targeted screening can represent a first step, in sight of the strengthening of this preventive action in the future.
Finally, when considering a targeted approach, it is important to promote the women uptake. Indeed the main critical issue in these cases is the low participation of high-risk individuals.
Interestingly, HIV rescreening in late pregnancy appeared as an economical worthwhile solution even in countries with low HIV burden. Consequently, these findings could have important implications in the policies of these countries, making rescreening a desirable approach at least for high-risk groups. On the contrary, the importance of HIV rescreening is widely assessed in developing countries, where this strategy is cost saving.
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